Cargando…

P657: PATHOGENESIS OF TYROSINE KINASE INHIBITOR–ASSOCIATED VASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Gover Proaktor, Ayala, Granot, Galit, Pasvolsky, Oren, Raanani, Pia, Leader, Avi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429008/ http://dx.doi.org/10.1097/01.HS9.0000969532.95758.de

Ejemplares similares

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Hypertension in cancer patients treated with anti-angiogenic based regimens
por: Wasserstrum, Yishay, et al.
Publicado: (2015)

Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors
por: Telerman, Alona, et al.
Publicado: (2021)

Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
por: Shacham Abulafia, Adi, et al.
Publicado: (2020)

Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
por: Berger, Tamar, et al.
Publicado: (2021)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells
por: Hershkovitz Rokah, Oshrat, et al.
Publicado: (2012)

Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
por: Janssen, L., et al.
Publicado: (2019)

A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
por: Kaddoura, Rasha, et al.
Publicado: (2023)

Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study
por: Sharman Moser, Sarah, et al.
Publicado: (2022)

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
por: Nguyen, Tien V, et al.
Publicado: (2018)

657. Diagnostic Utility of Dedicated Fungal Blood Cultures for Diagnosis of Candidemia
por: Yang, Bryant, et al.
Publicado: (2020)

Correction to Lancet Public Health 2022; 7: e657–69
Publicado: (2022)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study
por: Shargian, Liat, et al.
Publicado: (2022)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Diarrheal Morbidity During Hematopoietic Cell Transplantation: The Diagnostic Yield of Stool Cultures
por: Berger, Tamar, et al.
Publicado: (2021)

Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
por: Geiger, Karyn Revital, et al.
Publicado: (2022)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
por: Aghel, Nazanin, et al.
Publicado: (2017)

SUN-657 The Effect of Simvastatin on Glucose Metabolism in Primary Human Muscle Cells
por: Mäkinen, Selina, et al.
Publicado: (2020)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
por: Peled, Amnon, et al.
Publicado: (2013)

Energy spectra of $\pi^{+}$ mesons in the $pp -> np\pi^{+}$ reaction at 556 and 657 Mev
por: Meshcheriakov, M G, et al.
Publicado: (1956)

Melanosis coli: Harmless pigmentation? A case-control retrospective study of 657 cases
por: Liu, Zhong Hui, et al.
Publicado: (2017)

SAT-657 The Gut Microbiome Regulates Host Glucose Homeostasis via Peripheral Serotonin
por: Keating, Damien
Publicado: (2020)

FRI657 Case Series On GLP-1 Receptor Agonist Related Acute Pancreatitis
por: Kumar Kulkarni, Abhigna Uday, et al.
Publicado: (2023)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1cfl2gvihs5ecv3nml9rjomff9